Stock Track | Terns Pharmaceuticals (TERN) Soars 5.23% Pre-Market on Positive Analyst Ratings and Raised Price Targets

Stock Track

Nov 11

Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price targets. The stock's upward momentum comes amid growing optimism surrounding the company's potential in the healthcare sector.

Leading the charge, Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32. This vote of confidence from Mizuho analyst Graig Suvannavejh underscores the firm's bullish outlook on TERN's future prospects. Additionally, Barclays has raised its price target for Terns Pharmaceuticals to $28 from $27, while maintaining a Buy rating. Analyst Etzer Darout's decision to increase the target price signals growing confidence in the company's potential for growth and value creation.

The positive sentiment is further reinforced by a broader analyst report offering insights into healthcare companies, which includes Terns Pharmaceuticals alongside other sector players. This collective analyst attention and the consecutive positive ratings suggest that Wall Street is increasingly optimistic about Terns Pharmaceuticals' pipeline and market position, driving investor interest and contributing to the stock's pre-market rally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106211764"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106211764\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106211764?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 22:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106211764","market":"sg","top_or_hot":-1,"title":"Stock Track | Terns Pharmaceuticals (TERN) Soars 5.23% Pre-Market on Positive Analyst Ratings and Raised Price Targets","media":"Stock Track","content":"<p>Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price targets. The stock's upward momentum comes amid growing optimism surrounding the company's potential in the healthcare sector.</p>\n\n<p>Leading the charge, Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32. This vote of confidence from Mizuho analyst Graig Suvannavejh underscores the firm's bullish outlook on TERN's future prospects. Additionally, Barclays has raised its price target for Terns Pharmaceuticals to $28 from $27, while maintaining a Buy rating. Analyst Etzer Darout's decision to increase the target price signals growing confidence in the company's potential for growth and value creation.</p>\n\n<p>The positive sentiment is further reinforced by a broader analyst report offering insights into healthcare companies, which includes Terns Pharmaceuticals alongside other sector players. This collective analyst attention and the consecutive positive ratings suggest that Wall Street is increasingly optimistic about Terns Pharmaceuticals' pipeline and market position, driving investor interest and contributing to the stock's pre-market rally.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Terns Pharmaceuticals (TERN) Soars 5.23% Pre-Market on Positive Analyst Ratings and Raised Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Terns Pharmaceuticals (TERN) Soars 5.23% Pre-Market on Positive Analyst Ratings and Raised Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-11 22:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price targets. The stock's upward momentum comes amid growing optimism surrounding the company's potential in the healthcare sector.</p>\n\n<p>Leading the charge, Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32. This vote of confidence from Mizuho analyst Graig Suvannavejh underscores the firm's bullish outlook on TERN's future prospects. Additionally, Barclays has raised its price target for Terns Pharmaceuticals to $28 from $27, while maintaining a Buy rating. Analyst Etzer Darout's decision to increase the target price signals growing confidence in the company's potential for growth and value creation.</p>\n\n<p>The positive sentiment is further reinforced by a broader analyst report offering insights into healthcare companies, which includes Terns Pharmaceuticals alongside other sector players. This collective analyst attention and the consecutive positive ratings suggest that Wall Street is increasingly optimistic about Terns Pharmaceuticals' pipeline and market position, driving investor interest and contributing to the stock's pre-market rally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1106211764","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106211764","pubTimestamp":1762872743,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"个股追踪|Terns Pharmaceuticals(TERN)盘前飙升5.23%，因分析师正面评级和上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":1},"content_text":"Shares of Terns Pharmaceuticals, Inc. (TERN) are surging 5.23% in pre-market trading on Tuesday, as the biopharmaceutical company receives a boost from positive analyst ratings and increased price targets. The stock's upward momentum comes amid growing optimism surrounding the company's potential in the healthcare sector.\nLeading the charge, Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32. This vote of confidence from Mizuho analyst Graig Suvannavejh underscores the firm's bullish outlook on TERN's future prospects. Additionally, Barclays has raised its price target for Terns Pharmaceuticals to $28 from $27, while maintaining a Buy rating. Analyst Etzer Darout's decision to increase the target price signals growing confidence in the company's potential for growth and value creation.\nThe positive sentiment is further reinforced by a broader analyst report offering insights into healthcare companies, which includes Terns Pharmaceuticals alongside other sector players. This collective analyst attention and the consecutive positive ratings suggest that Wall Street is increasingly optimistic about Terns Pharmaceuticals' pipeline and market position, driving investor interest and contributing to the stock's pre-market rally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}